SYFda0301092ea74ab69c77593904b3bed0

UnknownPhase 1

Single dose, open-label, laboratory blinded, randomized, 2-t...

Laboratorios Cinfa S.A.Source

Laboratorios Cinfa S.A.

CTIS (EMA)

Compare

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

1

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
January 26, 2026
Actual (reported)

Conditions

No medical condition

Sponsors & Collaborators

Laboratorios Cinfa S.A.
Industrylead

Study Sites (1)

Quinta-Analytica s.r.o.

Prague, 102 00, Czechia

Jiří Juchelka00420773791463 jiri.juchelka@quinta.cz

Central Study Contacts

Rubén Rubén Estepa Sanz

948335005 ruben.estepa@cinfa.com

Study Design

Study Type: interventional
Phase: phase 1

Study Record Dates

First Submitted

January 26, 2026

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2025-521732-11-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-30 06:20:39 UTC

Locations

CZ(1)

SYFd56d214e59c947139f4b57c9ed3ba237

Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.

Phase 1Unknown

SYFc544fedbe1cd41049beadda9636ec7e9

Comparative Pharmacokinetic of S221237 Tablets in Healthy Participants Under Fed Conditions

Phase 1Unknown

SYF7859a6b51836410c98a47e1acfe7c0c1

Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fed Conditions

Phase 1Unknown

SYF8a6fd1a9efc5494eb775b2f066d2519a

Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fasting Conditions

Phase 1Unknown

SYFaa96b6900d074ae091da8627280354b0

Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions

Phase 1Unknown

SYF339cb9157fc7497280fcdfc24729d9b2

Bioequivalence of Eltrombopag 25 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.

Phase 1Unknown

SYFe503cac5e5c1442984418dc034888aed

Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions

Phase 1Unknown

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations